Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation

Pediatric Transplantation

Volumn 12, Issue 5, 2008, Pages 541-549

  Weintraub, Lauren ^a,c   Li, Li ^a   Kambham, Neeraja ^b   Alexander, Steven ^a   Concepcion, Waldo ^c   Miller, Kim ^a   Wong, Cynthia ^a   Salvatierra, Oscar ^c   Sarwal, Minnie ^a  

^a Departments of Pediatrics   (United States)

^b Pathology and Surgery

^c STANFORD UNIVERSITY   (United States)

Author keywords

acute rejection; Calcineurin inhibitors; Pediatric renal transplantation; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CLINICAL ARTICLE; COLON ULCER; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MOUTH ULCER; PATIENT SELECTION; PROTEINURIA; RENAL GRAFT DYSFUNCTION; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BIOPSY; DRUG ANTAGONISM; GRAFT REJECTION; METHODOLOGY; PEDIATRICS; RETROSPECTIVE STUDY;

ADOLESCENT; BIOPSY; CALCINEURIN; CHILD; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PATIENT SELECTION; PEDIATRICS; PROTEINURIA; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 55949095133     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00847.x     Document Type: Article

References (42)

1. RACUSEN LC, SOLEZ K, COLVIN RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713-723.
2. SHARMA VK, BOLOGA RM, Xu GP, et al. Intragraft TGF-beta 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996: 49: 1297-1303.
3. BABOOLAL K, JONES GA, JANEZIC A, GRIFFITHS DR, JUREWICZ WA. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002: 61: 686-696.
4. KAMBHAM N, NAGARAJAN S, SHAH S, Li L, SALVATIERRA O, SARWAL MM. A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies. Clin J Am Soc Nephrol 2007: 2: 135-142.
5. BUMBEA V, KAMAR N, RIBES D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005: 20: 2517-2523.
6. CITTERLO F, SCATA MC, VIOLI P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003: 35: 1292-1294.
7. DIEKMANN F, BUDDE K, OPPENHEIMER F, FRITSCHE L, NEUMAYER HH, CAMPISTOL JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004: 4: 1869-1875.
8. WEBER T, ABENDROTH D, SCHELZIG H. Rapamycin rescue therapy in patients after kidney transplantation: First clinical experience. Transpl Int 2005: 18: 151-156.
9. LAI WJ, CHIANG YJ, CHEN Y, CHU SH. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? Transplant Proc 2004: 36: 2056-2057.
10. Wu MS, CHANG CT, HUNG CC. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant 2005: 19: 236-242.
11. EGIDI MF, COWAN PA, NASEER A, GABER AO. Conversion to sirolimus in solid organ transplantation: A single-center experience. Transplant Proc 2003: 35(Suppl. 3): 131S-137S.
12. MORELON E, KREIS H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003: 35(Suppl. 3): 52S-57S.
13. MARTINEZ-MIER G, MENDEZ-LOPEZ MT, ESTRADA-OROS J, et al. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients. Arch Med Res 2006: 37: 635-638.
14. FISCHEREDER M, GRAEB C, KRuger B, et al. Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc 2006: 38: 1295-1297.
15. PEDDI VR, JENSIK S, PESCOVITZ M, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005: 19: 130-136.
16. STALLONE G, INFANTE B, SCHENA A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005: 16: 3755-3762.
17. FALGER JC, MUELLER T, ARBEITER K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006: 10: 565-569.
18. HOCKER B, FENEBERG R, KOPF S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006: 10: 593-601.
19. GARCIA CD, BITTENCOURT VB, ALVES AB, et al. Conversion to sirolimus in pediatric renal transplantation recipients. Transplant Proc 2006: 38: 1901-1903.
20. DIEKMANN F, WAISER J, FRITSCHE L, Dragun D, NEUMAYER HH, BUDDE K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001: 33: 3234-3235.
21. SUNDBERG AK, ROHR MS, HARTMANN EL, ADAMS PL, STRATTA RJ. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 2004: 18(Suppl. 12): 61- 66.
22. BUHAESCU I, IZZEDINE H, COVIC A. Sirolimus - Challenging current perspectives. Ther Drug Monit 2006: 28: 577-584.
23. SCHWARTZ GJ, HAYCOCK GB, EDELMANN CM, Jr., Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976: 58: 259-263. Weintraub et al. 548
24. ISONIEMI H, TASKINEN E, HAYRY P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994: 58: 1195-1198.
25. SCHACHTER AD, MEYERS KE, SPANEAS LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004: 8: 171-177.
26. BRATTSTROM C, SAWE J, TYDEN G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1997: 19: 397-406.
27. ZIMMERMAN JJ, KAHAN BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997: 37: 405-415.
28. CATTANEO D, PERICO N, GASPARI F, GOTTI E, REMUZZI G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002: 62: 1060-1067.
29. SENNESAEL JJ, BOSMANS JL, BOGERS JP, VERBEELEN D, VERPOOTEN GA. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005: 80: 1578-1585.
30. GONWA TA, HRICIK DE, BRINKER K, GRINYO JM, SCHENA FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002: 74: 1560-1567.
31. OBERBAUER R, SEGOLONI G, CAMPISTOL JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005: 18: 22-28.
32. RUIZ JC, CAMPISTOL JM, SANCHEZ-FRUCTUOSO A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006: 21: 3252-3257.
33. RUIZ JC, DIEKMANN F, CAMPISTOL JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study. Transplant Proc 2005: 37: 3833-3835.
34. BUTANI L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004: 78: 1362-1366.
35. IZZEDINE H, BROCHERIOU I, FRANCES C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005: 353: 2088-2089.
36. LETAVERNIER E, PERALDI MN, PARIENTE A, MORELON E, LEGENDRE C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005: 80: 1198- 1203.
37. BORATYNSKA M, BANASIK M, WATOREK E, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006: 38: 101- 104.
38. SAURINA A, CAMPISTOL JM, PIERA C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006: 21: 488-493.
39. vAN dEN AKKER JM, WETZELS JF, HOITSMA AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006: 70: 1355-1357.
40. FLECHNER SM, GOLDFARB D, MODLIN C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002: 74: 1070-1076.
41. STEPHANY BR, AUGUSTINE JJ, KRISHNAMURTHI V, et al. Differences in proteinuria and graft function in de novo sirolimusbased vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006: 82: 368-374.
42. DIEKMANN F, CAMPISTOL JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006: 21: 562- 568.